Abstract: Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease in the world and also the number one liver disease in China.Its incidence rate shows an upward trend year by year.If the degree of liver steatosis is aggravated,liver fibrosis may occur and eventually lead to liver cirrhosis and even hepatocarcinoma.All these are serious hazards to people's health.In recent years,many new changes have taken place in the diagnosis and treatment of MAFLD,which has become a research hotspot.This article reviews the global harm and health burden of fatty liver disease,the change of fatty liver naming and the diagnosis and treatment of metaboli-associated fatty liver disease.The purpose of this study is to provide reference for the early diagnosis,disease evaluation and new drug development of metabolic-associated fatty liver disease.

Key words: metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, diagnosis, treatment